Rimiducid
- Generic Name
- Rimiducid
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C78H98N4O20
- CAS Number
- 195514-63-7
- Unique Ingredient Identifier
- H564L1W5J2
- Background
Rimiducid is a lipid-permeable tacrolimus analogue and a protein dimerizer. It was designed to overcome limitations of current cellular immunotherapies used for cancer and other blood disorders by enhancing the control of the immune cell activity and function. When administered via chemically-inducible dimerization (CID) technologies, rimiducid binds to switch proteins and dimerizes them, triggering downstream signaling cascade. The combination use of rimiducid with immunotherapies for enhanced therapeutic effectiveness is currently under investigation.
- Indication
Investigated for use/treatment in bone marrow transplant and graft versus host disease.
- Associated Conditions
- -
- Associated Therapies
- -
Phase 1 Dose Escalation and Expansion Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Patients With Advanced Solid Tumors (TROPIKANA)
- Conditions
- Interventions
- First Posted Date
- 2023-10-04
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 54
- Registration Number
- NCT06066424
- Locations
- ๐บ๐ธ
M D Anderson Cancer Center, Houston, Texas, United States
P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies
- First Posted Date
- 2023-08-28
- Last Posted Date
- 2024-08-21
- Lead Sponsor
- Poseida Therapeutics, Inc.
- Target Recruit Count
- 120
- Registration Number
- NCT06014762
- Locations
- ๐บ๐ธ
University of Cincinnati, Cincinnati, Ohio, United States
๐บ๐ธVanderbilt University Medical Center, Nashville, Tennessee, United States
๐บ๐ธPrisma Health - Upstate Cancer Institute, Greenville, South Carolina, United States
P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Advanced or Metastatic Solid Tumors
- First Posted Date
- 2022-02-14
- Last Posted Date
- 2024-04-23
- Lead Sponsor
- Poseida Therapeutics, Inc.
- Target Recruit Count
- 100
- Registration Number
- NCT05239143
- Locations
- ๐บ๐ธ
University of California, Irvine Medical Center, Irvine, California, United States
๐บ๐ธUniversity of Maryland Cancer Center, Baltimore, Maryland, United States
๐บ๐ธCedars Sinai Medical Center, Los Angeles, California, United States
P-BCMA-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2021-07-14
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- Poseida Therapeutics, Inc.
- Target Recruit Count
- 231
- Registration Number
- NCT04960579
- Locations
- ๐บ๐ธ
Advocate Aurora Health, Park Ridge, Illinois, United States
๐บ๐ธUniversity of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, Maryland, United States
๐บ๐ธUniversity of Iowa, Iowa City, Iowa, United States
P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC)
- Conditions
- Interventions
- First Posted Date
- 2020-01-31
- Last Posted Date
- 2024-04-18
- Lead Sponsor
- Poseida Therapeutics, Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT04249947
- Locations
- ๐บ๐ธ
University of California San Diego, San Diego, California, United States
๐บ๐ธUniversity of California San Francisco, San Francisco, California, United States
๐บ๐ธDana-Farber Cancer Institute, Boston, Massachusetts, United States
T-cells Expressing an Anti-SLAMF7 CAR for Treating Multiple Myeloma
- First Posted Date
- 2019-05-22
- Last Posted Date
- 2021-09-09
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 13
- Registration Number
- NCT03958656
- Locations
- ๐บ๐ธ
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Rivogenlecleucel Donor Lymphocyte Immunotherapy in Treating Patients With Recurrent Blood Cancers After Stem Cell Transplant
- Conditions
- Myelodysplastic/Myeloproliferative Neoplasm, UnclassifiableRecurrent Acute Myeloid LeukemiaRecurrent Chronic Myelogenous Leukemia, BCR-ABL1 PositiveMyeloproliferative NeoplasmRecurrent Acute Lymphoblastic LeukemiaRecurrent Chronic Lymphocytic LeukemiaRecurrent Myelodysplastic SyndromeAcute Bilineal LeukemiaMyelodysplastic/Myeloproliferative NeoplasmRecurrent Acute Biphenotypic Leukemia
- Interventions
- First Posted Date
- 2019-01-16
- Last Posted Date
- 2020-08-14
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Registration Number
- NCT03807063
- Locations
- ๐บ๐ธ
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Long Term Follow-up Study for Patients Enrolled on the BP-004 Clinical Study
- Conditions
- Interventions
- First Posted Date
- 2018-11-07
- Last Posted Date
- 2023-09-26
- Lead Sponsor
- Bellicum Pharmaceuticals
- Target Recruit Count
- 187
- Registration Number
- NCT03733249
- Locations
- ๐ฎ๐น
IRCCS Ospedale Pediatrico Bambino Gesรน, Rome, Italy
Study of Haplo-HSCT + Rivogenlecleucel vs Haplo-HSCT + Post Transplant Cyclophosphamide in Patients With AML or MDS
- Conditions
- Interventions
- First Posted Date
- 2018-10-09
- Last Posted Date
- 2023-09-29
- Lead Sponsor
- Bellicum Pharmaceuticals
- Target Recruit Count
- 1
- Registration Number
- NCT03699475
- Locations
- ๐บ๐ธ
TriStar Bone Marrow Transplant, LLC, Nashville, Tennessee, United States
๐บ๐ธMethodist Healthcare System of San Antonio Clinical Trials Office, San Antonio, Texas, United States
BPX-501 T Cells Infused Post Stem Cell Transplant in Pediatrics With Non-Malignant Disorders Ineligible for BPU004 Study
- First Posted Date
- 2018-08-21
- Last Posted Date
- 2020-10-05
- Lead Sponsor
- Bellicum Pharmaceuticals
- Registration Number
- NCT03639844
- Locations
- ๐บ๐ธ
Children's Hospital Los Angeles, Los Angeles, California, United States
๐บ๐ธStanford University; Division of Pediatric Stem Cell Transplant & Regenerative Medicine, Palo Alto, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.